Abeona Therapeutics (ABEO) director Alland Leila sells 11,000 shares

Rhea-AI Filing Summary

Abeona Therapeutics director Alland Leila reported an open-market sale of company stock. On this Form 4, Leila sold 11,000 shares of Abeona Therapeutics common stock in a non-derivative, open-market transaction at a weighted average price of $5.917 per share.

The sale occurred through multiple trades on a single day at prices ranging from $5.915 to $5.9334 per share. After these transactions, Leila directly holds 162,614 shares of Abeona Therapeutics common stock.

Insider Trade Summary

Net Seller: 11,000 shares ($65,087)

Net Sell 1 txn

Insider Alland Leila

Role null

Sold 11,000 shs ($65K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,000	$5.917	$65K

Holdings After Transaction: Common Stock — 162,614 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,000 shares Weighted average sale price: $5.917 per share Sale price range: $5.915–$5.9334 per share +2 more

5 metrics

Shares sold 11,000 shares Open-market sale of common stock

Weighted average sale price $5.917 per share Average price across multiple trades

Sale price range $5.915–$5.9334 per share Range of individual trade prices

Shares owned after transaction 162,614 shares Direct ownership following sale

Net buy/sell shares -11,000 shares Net effect of reported transactions

Key Terms

weighted average price, open-market sale, non-derivative, Common Stock

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

""transaction_type": "non-derivative""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:31 PM Accepted by SEC EDGAR 07/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alland Leila

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		S		11,000	D	$5.917(1)	162,614	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.915 to $5.9334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Leila Alland	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Alland Leila report for Abeona Therapeutics (ABEO)?

Alland Leila reported selling 11,000 shares of Abeona Therapeutics common stock. The transaction was an open-market, non-derivative sale disclosed on a Form 4, reflecting routine portfolio activity rather than any grant, option exercise, or gift transaction.

At what price did Alland Leila sell Abeona Therapeutics (ABEO) shares?

The shares were sold at a weighted average price of $5.917 per share. Individual trades occurred within a narrow range from $5.915 to $5.9334, indicating several small executions rather than a single block trade during the trading session.

How many Abeona Therapeutics (ABEO) shares does Alland Leila hold after this sale?

After the reported sale, Alland Leila directly holds 162,614 shares of Abeona Therapeutics common stock. This post-transaction balance, disclosed in the Form 4, shows that a substantial number of shares remains owned following the 11,000-share disposition.

What type of transaction is shown in Alland Leila’s Abeona Therapeutics (ABEO) Form 4?

The Form 4 records a non-derivative open-market sale of common stock. It is classified under transaction code "S," which the filing describes as a sale in an open market or private transaction, rather than an option exercise or derivative conversion.

Did Alland Leila’s Abeona Therapeutics (ABEO) sale involve multiple trade prices?

Yes. The filing notes the price as a weighted average because the 11,000 shares were sold in multiple trades. Those trades occurred at prices between $5.915 and $5.9334, and the insider offers to provide exact breakdowns upon request.